KCM
SLXP

Kingdon Capital Management’s SALIX PHARMACEUTICALS LTD DEL SLXP Stock Holding History

Kingdon Capital Management’s Portfolio SLXP Stock Details SLXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-75,000
Closed -$11.7M – 194
2014
Q3 		$11.7M Sell
75,000
-175,000
-70% -$25.4M 0.53% 49
2014
Q2 		$30.8M Buy
+250,000
New +$27.6M 1.18% 14

Other funds holding SLXP

PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
YCMGA
York Capital Management Global Advisors New York $87.8M AUM 45.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Kingdon Capital Management's SLXP Position: Q1 2015 in Review

Kingdon Capital Management sold out of SALIX PHARMACEUTICALS LTD DEL (SLXP) in Q1 2015, closing a stake of 179,600 shares — an estimated $20.6M sold.

Kingdon Capital Management first reported a position in SLXP in Q2 2013 and held it in 6 quarters. The position peaked at $29.9M in Q3 2014. 298 funds tracked by Wall St. Rank hold SLXP as of Q1 2015.

  • Kingdon Capital Management reported no remaining SALIX PHARMACEUTICALS LTD DEL position as of Q1 2015 after selling out during the quarter.
  • Kingdon Capital Management sold 179,600 SALIX PHARMACEUTICALS LTD DEL shares in Q1 2015, an estimated $20.6M.
  • Kingdon Capital Management first reported a position in SALIX PHARMACEUTICALS LTD DEL in Q2 2013 and held it in 6 quarters.
  • Kingdon Capital Management's SALIX PHARMACEUTICALS LTD DEL position peaked at $29.9M in Q3 2014.
  • 298 funds tracked by Wall St. Rank held SALIX PHARMACEUTICALS LTD DEL as of Q1 2015.

Based on Kingdon Capital Management's 13F filing for Q1 2015, filed 15 May 2015.